Lev Pharmaceuticals to Present at the Collins Stewart 4th Annual Growth Conference

July 2, 2008 9:37 AM EDT

NEW YORK--(BUSINESS WIRE)--

Lev Pharmaceuticals, Inc. ("Lev" or the "Company") (OTCBB: LEVP) announced today that Joshua Schein, Ph.D., chief executive officer of Lev will present at the Collins Stewart 4th Annual Growth Conference, being held July 8-10 at the Mandarin Oriental Hotel in New York City, NY. Dr. Schein will present a corporate progress report, including an update on the Company's lead product candidate, Cinryze(TM) (C1 inhibitor (human)). The Lev presentation is scheduled to begin at 10:00 a.m. Eastern Standard Time on Thursday, July 10th.

The Lev presentation will be webcast live and may be accessed by visiting the Investor Relations section of the Company's website at www.levpharma.com. The presentation will also be available on the Lev website in replay format for a limited time following the conference.

About Lev Pharmaceuticals, Inc.

Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's lead product candidate, Cinryze(TM) (C1 inhibitor (human)), is being developed as a replacement therapy for hereditary angioedema (HAE), also known as C1 inhibitor deficiency. Cinryze(TM) has been granted orphan drug status for the acute and prophylactic treatment of HAE, potentially securing, upon approval, market exclusivity for seven years. Additionally, Lev is in the process of prioritizing its C1 inhibitor development platform for the treatment of selective other diseases and disorders in which inflammation is known or believed to play an underlying role.

For more information about Lev, C1 inhibitor, or HAE, please contact Lev directly at 212-682-3096, or visit Lev's website at www.levpharma.com.

Forward Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our plans and objectives of management are forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including risks related to new information arising out of clinical trial results, the risk that the safety and/or efficacy results of existing clinical trials for Cinryze(TM) will not support approval for a biologics license, the risk that FDA may require us to conduct additional clinical trials for Cinryze(TM), the risk that FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that FDA will not approve a product for which a biologics license has been applied, our heavy dependence on the success of Cinryze(TM), our dependence on our suppliers, our dependence on third parties to manufacture Cinryze(TM), obtaining regulatory approval to market Cinryze(TM), market acceptance of Cinryze(TM), maintaining the orphan drug status associated with Cinryze(TM), the risks associated with dependence upon key personnel, and our ability to obtain additional funding to support our business activities. These and other risks are described in greater detail in the "Risk Factors that May Affect Results" section of our filings with the SEC. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. We do not assume any obligation to update any forward-looking statements.

Source: Lev Pharmaceuticals, Inc.

Related Categories

Press Releases

Stocks Mentioned

Related Entities

• Collins Stewart

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?